Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
CNS Oncology|November 30, 2019
Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphomaMeetakshi Gupta, Tejpal Gupta, Nilendu Purandare, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|January 21, 2022
Prognostic impact of semantic MRI features on survival outcomes in molecularly subtyped medulloblastomaArchya Dasgupta, Tejpal Gupta, Madan Maitre, et al.
Lung India : Official Organ of Indian Chest Society|January 11, 2018
Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?Amit Joshi, Vijay Patil, Vanita Noronha, et al.
Ecancermedicalscience|November 7, 2017
Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapyVanita Noronha, Vijay Patil, Amit Joshi, et al.
Chemotherapy Research and Practice|December 5, 2017
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?Amit Joshi, Vanita Noronha, Vijay M Patil, et al.
Pediatric Blood & Cancer|December 15, 2024
Outcomes Based on Histological Tumor Necrosis and Predictive Clinical and Laboratory Parameters for Necrosis in Children With Osteosarcoma Treated on a Non-High Dose Methotrexate-Based Chemotherapy BackboneBadira Cheriyalinkal Parambil, Poonam Khemani, Ajay Puri, et al.
ESMO Open|August 2, 2017
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, et al.
Cancer Medicine|February 16, 2021
A real-world data of Immune checkpoint inhibitors in solid tumors from IndiaVanita Noronha, George Abraham, Vijay Patil, et al.
South Asian Journal of Cancer|March 24, 2025
Efficacy and Safety of Low-Dose Nivolumab in Treatment of Advanced Solid Tumors: A Retrospective Audit from Resource-Constrained SettingsAmit Kumar, Akhil Kapoor, Vanita Noronha, et al.
South Asian Journal of Cancer|December 31, 2025
Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, IndiaAtul Tiwari, Ajay Kumar Singh, Vanita Noronha, et al.
Pageof 9